Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HealthEquity enters the final stretch before its December earnings with a subtle but consistent shift in positioning: short sellers have been adding exposure for six weeks, options markets have turned more defensive, and the stock is trading roughly 22% below where analysts think it should be.
The short-interest story is not alarming, but it has become harder to ignore. Short interest has risen 18% over the past month, reaching 5.8% of the free float. The pace picked up this week, with shares short up 3.4% over the five-session period to around 5 million. That is a steady grind rather than a sudden attack, but the direction has been consistent since late August. Borrow conditions give shorts no trouble: cost to borrow is just 0.49%, firmly in the low category, and availability is wide at roughly 647% of short interest, meaning for every share borrowed there are more than six still sitting in the lending pool. There is no squeeze pressure here.
Options markets tell a more cautious story. The put/call ratio has climbed to 0.89, well above its 20-day average of 0.59. The shift is pronounced: for most of September, the ratio was running between 0.11 and 0.24, with calls dominating. From late September onward, puts caught up sharply, with the ratio crossing 1.0 on several days. The z-score of 0.77 keeps this short of an extreme read, but the directional swing over a matter of weeks is notable. The ORTEX short score has also edged above the 50 mark for the first time in recent weeks, reaching 50.3 on October 8, up from 47.1 two weeks ago. None of these individually is alarming; together they paint a picture of growing caution.
The Street remains broadly constructive, though the stock's pullback has opened a gap between price and targets that is hard to miss. The mean analyst price target is $119, implying roughly 29% upside from the current $92.61. Barclays raised its target to $115 in mid-September while maintaining an Overweight rating. Deutsche Bank went further after the August earnings, lifting its target to $142 on a Buy. The broad direction of analyst revisions has been upward since spring. Bulls point to HSA member growth of 8% year on year, custodial assets up 14%, and renewal rates above 90%, with only around 9% of HSA members currently investing their balances, leaving meaningful room to deepen wallet share through products like SimplyInvest. Bears flag sensitivity to a softer jobs market, where slower high-income employment growth hits contribution volumes directly, and point to interest-rate and margin risk in a potential recessionary scenario. Valuation multiples are undemanding relative to the growth profile: the stock trades at about 17.5 times earnings and 12.2 times EV/EBITDA, both of which have drifted slightly lower over the past month.
Retail attention to HealthEquity has picked up sharply. The ORTEX alt-data layer shows a Wikipedia-views z-score of 3.8 against the stock's own 90-day history, meaning the level of retail interest is well above what has been typical. That reading is from late September and covers attention, not a revenue indicator, but it is unusual for a mid-sized benefits administrator to generate that kind of spike.
The ownership picture is broadly stable, though one move is worth noting. Wasatch Advisors, a specialist growth manager with roughly 9.6% of shares, filed a 13G amendment on October 9, reducing its disclosed stake from 9.5% to 8.5% of the class. The current institutional data shows Wasatch holding around 8 million shares, still comfortably the second-largest holder behind BlackRock at 13.6%. Wasatch's trimming is a passive-style 13G filing, not an activist move, and the reduction is modest relative to their overall position size. All 13D/G disclosures are event-driven around the 5% threshold, so the position could have moved further since filing. On the insider side, October 6 saw a cluster of tax-withholding transactions from senior management including the CEO and CFO, all coded as F-type filings. These are compensation mechanics tied to equity vesting, not discretionary sales, and carry little informational weight.
HQY reports next on December 1. With short interest building steadily, options positioning rotating toward puts, and Wasatch trimming, the question heading into that print is whether the August selloff, the stock fell 7.7% on the day and a further 5.4% over the following week after its last earnings report, remains fresh enough in institutional memory to keep pressure on.
See the live data behind this article on ORTEX.
Open HQY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
